When we obtain multiple scores from each participant, we can distinguish two ways in which participants differ:
These correspond to:
| Participant | A₁ | A₂ | ΔA (A₂ − A₁) | Mean |
|---|---|---|---|---|
| P1 | 40 | 50 | +10 | 45 |
| P2 | 50 | 60 | +10 | 55 |
| P3 | 60 | 70 | +10 | 65 |
| P4 | 70 | 80 | +10 | 75 |
| Mean | 55 | 65 | +10 | 60 |
High between-participant variability / zero residual variability
| Participant | A₁ | A₂ | ΔA (A₂ − A₁) | Mean |
|---|---|---|---|---|
| P1 | 40 | 80 | +40 | 60 |
| P2 | 50 | 70 | +20 | 60 |
| P3 | 60 | 60 | 0 | 60 |
| P4 | 70 | 50 | –20 | 60 |
| Mean | 55 | 65 | +10 | 60 |
Zero between-participant variability / high residual variability
The key distinction:
| Example 1 | Example 2 | |
|---|---|---|
| Mean of A₁ | 55 | 55 |
| Mean of A₂ | 65 | 65 |
| Mean difference | +10 | +10 |
| Between-participant variability | High | Zero |
| Residual variability | Zero | High |
When investigating treatment effects, we are primarily interested in whether participants' scores change systematically between conditions
By removing individual differences from the error term, within-participants ANOVA can reduce experimental error, increasing the F ratio and improving statistical power
This is the fundamental additional step required when calculating the within-participants ANOVA
The important change: Within-participants ANOVA uses residual variance rather than within-group variance as the denominator of the F-ratio
\(MS_{BETWEEN}\) represents between-group variance.
\(MS_{RESIDUAL}\) represents residual variance after accounting for individual differences.
A psychologist investigates whether misinformation warnings improve people's ability to distinguish between true and false information on social media
Each row contains three scores from the same participant, rather than three independent groups of participants
Grand total: \(\Sigma Y= 270 + 315 + 350 = 935\)
Grand mean: \(\bar Y=62.33\)
Grand total: \(\Sigma Y= 270 + 315 + 350 = 935\)
\(N\) = the total number of observations across all treatment conditions
\(N_A\) = the number of observations in each treatment condition
The calculations agree!
\[SS_{BETWEEN},\quad SS_{WITHIN},\quad SS_{TOTAL}\]
The key additional step:
\[ SS_{WITHIN}=SS_{SUBJECTS}+SS_{RESIDUAL} \]
\[ \boxed{SS_{RESIDUAL}=SS_{WITHIN}-SS_{SUBJECTS}} \]
We've already seen that participants differ in their overall performance, irrespective of treatment condition
Number of scores contributed by each participant
Recall:
\[ SS_{WITHIN}=SS_{SUBJECTS}+SS_{RESIDUAL} \]
Rearranging:
\[ SS_{RESIDUAL}=SS_{WITHIN}-SS_{SUBJECTS} \]
Substituting:
\[ SS_{RESIDUAL}=650-260 \]
\[ \boxed{SS_{RESIDUAL}=390} \]
The important point: Of the 650 units of within-group variability, 260 are attributable to systematic differences between participants. The remaining 390 represent residual variability.
We can now partition total variability into three components:
\[ SS_{TOTAL}=SS_{BETWEEN}+SS_{SUBJECTS}+SS_{RESIDUAL} \]
Substituting our values:
\[ 1,293.33=643.33+260+390 \]
| Source of variability | Sum of squares |
|---|---|
| Between groups (treatments) | 643.33 |
| Between participants | 260.00 |
| Residual | 390.00 |
| Total | 1,293.33 |
\[ df_{BETWEEN}=a-1 \]
\[ df_{WITHIN}=N-a \]
\[ df_{TOTAL}=N-1 \]
Where:
\(a\) = number of treatment conditions
\(N\) = total number of observations
\[ a=3,\qquad N=15 \]
\[ \begin{aligned} df_{BETWEEN}&=3-1=\boxed{2}\\[6pt] df_{WITHIN}&=15-3=\boxed{12}\\[6pt] df_{TOTAL}&=15-1=\boxed{14} \end{aligned} \]
\[ df_{WITHIN}=df_{SUBJECTS}+df_{RESIDUAL} \]
\[ df_{SUBJECTS}=s-1 \]
\[ df_{SUBJECTS}=5-1=\boxed{4} \]
\[ df_{RESIDUAL}=df_{WITHIN}-df_{SUBJECTS} \]
\[ df_{RESIDUAL}=12-4=\boxed{8} \]
The important point: Of the 12 within-group degrees of freedom, four are associated with differences between participants, leaving eight for residual variability.
\[ df_{RESIDUAL}=(a-1)(s-1) \]
\[ df_{RESIDUAL}=(3-1)(5-1) \]
\[ df_{RESIDUAL}=2\times4 \]
\[ \boxed{df_{RESIDUAL}=8} \]
We can check our calculations by confirming that the degrees of freedom sum to the total.
\[ df_{TOTAL}=df_{BETWEEN}+df_{SUBJECTS}+df_{RESIDUAL} \]
\[ 14=2+4+8 \]
| Source of variability | SS | df |
|---|---|---|
| Between groups (treatments) | 643.33 | 2 |
| Between participants | 260.00 | 4 |
| Residual | 390.00 | 8 |
| Total | 1,293.33 | 14 |
The degrees of freedom and sums of squares both add up correctly
\[ MS_{BETWEEN}=\frac{643.33}{2}=321.67 \]
\[ MS_{RESIDUAL}=\frac{390}{8}=48.75 \]
\[ F=\frac{MS_{BETWEEN}}{MS_{RESIDUAL}} =\frac{321.67}{48.75} \approx\boxed{6.60} \]
\[ F_{obtained}=6.60 \]\[ F_{critical}(2,8)=4.46 \]\[ 6.60 > 4.46 \]
Decision: Reject \(H_0\)
| Source of variability | SS | df | MS | F |
|---|---|---|---|---|
| Between groups (treatments) | 643.33 | 2 | 321.67 | 6.60 |
| Between participants | 260.00 | 4 | 65.00 | — |
| Residual | 390.00 | 8 | 48.75 | — |
| Total | 1293.33 | 14 |
Like between-participants ANOVA, within-participants ANOVA relies on several assumptions:
The important difference: Sphericity replaces the homogeneity-of-variance assumption used in between-participants ANOVA
Sphericity concerns the variability of the difference scores between pairs of treatment conditions
For our misinformation experiment, we have three conditions:
\(A_1\): No warning
\(A_2\): Generic warning
\(A_3\): Specific warning
There are three possible pairwise differences:
\[ A_2-A_1,\qquad A_3-A_1,\qquad A_3-A_2 \]
The assumption of sphericity requires:
\[ \boxed{ \sigma^2_{A_2-A_1} = \sigma^2_{A_3-A_1} = \sigma^2_{A_3-A_2} } \]
In other words, the population variances of these difference scores must be equal
Sphericity is automatically satisfied when there are only two treatment conditions, because there is only one set of difference scores
| Participant | A₂ − A₁ | A₃ − A₁ | A₃ − A₂ |
|---|---|---|---|
| P1 | 15 | 20 | 5 |
| P2 | −5 | 15 | 20 |
| P3 | 15 | 10 | −5 |
| P4 | 0 | 20 | 20 |
| P5 | 20 | 15 | −5 |
For our hypothetical data, the sample variances are:
\[ s^2_{A_2-A_1}=117.5 \]
\[ s^2_{A_3-A_1}=17.5 \]
\[ s^2_{A_3-A_2}=157.5 \]
These differ considerably, although unequal sample variances do not by themselves establish that population sphericity has been violated
Sphericity can be assessed using Mauchly's test.
Null hypothesis: The assumption of sphericity holds
Alternative hypothesis: The assumption of sphericity is violated
As with Shapiro–Wilk and Levene's tests, a non-significant result does not signify that the assumption is satisfied
| Result | Interpretation |
|---|---|
| p > .05 | Insufficient evidence that sphericity is violated |
| p < .05 | Evidence that sphericity is violated |
Greenhouse–Geisser correction: Adjusts the degrees of freedom to account for departures from sphericity
Huynh–Feldt correction: An alternative adjustment that is generally less conservative
These corrections do not change the calculated F ratio itself. Instead, they modify the degrees of freedom used to determine statistical significance
As with between-participants ANOVA, we can use planned comparisons to test specific hypotheses about differences between treatment conditions.
Planned comparisons are specified before examining the results
For comparisons between two conditions, we can use a paired-samples t-test, with an appropriate adjustment if multiple comparisons are conducted
Post-hoc tests allow us to investigate which treatment conditions differ following an ANOVA.
Unlike planned comparisons, post-hoc tests are not restricted to comparisons specified in advance
Typically, we examine all possible pairwise comparisons between treatment conditions.
Conducting multiple comparisons increases the risk of Type I errors, so an appropriate adjustment is required (e.g., the Bonferroni correction)